<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00845221</url>
  </required_header>
  <id_info>
    <org_study_id>GLIVEC PHASE IV</org_study_id>
    <nct_id>NCT00845221</nct_id>
  </id_info>
  <brief_title>Glivec in Pediatric Chronic Myeloid Leukemia (CML)</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>Poitiers University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Poitiers University Hospital</source>
  <brief_summary>
    <textblock>
      It is a phase 4 study, not randomised and multicentric. Within 2 months after the diagnosis,&#xD;
      the patients daily receive imatinib by oral way during at least 1 year (260mg/m² once a day),&#xD;
      i.e. until the cytogenetic analysis.&#xD;
&#xD;
      Beyond 1 year of treatment, if a haematological relapse or a loss of the cytogenetic response&#xD;
      is observed, the nature of the treatment suggested to the patient is left with the&#xD;
      appreciation of the investigator.&#xD;
&#xD;
      Later on, discontinuation of imatinib is discussed if a molecular remission (negative RT-PCR)&#xD;
      is obtained and maintained for at least 2 years.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>July 2004</start_date>
  <primary_completion_date type="Actual">November 2011</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">44</enrollment>
  <condition>Chronic Myeloid Leukemia</condition>
  <arm_group>
    <arm_group_label>Imatinib</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Imatinib mesylate 100 mg (Glivec)</intervention_name>
    <description>260 mg/m2/day tablets</description>
    <arm_group_label>Imatinib</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Old &lt; 18 years, male or female.&#xD;
&#xD;
          -  Chronic myeloid leukaemia confirmed on the cytogenetic level by the presence of the&#xD;
             translocation t(9; 22) (q34; q11) or by the presence of transcript BCR-ABL in the&#xD;
             event of absence of description of the translocation t(9; 22) (q34; q11).&#xD;
&#xD;
          -  Chronic phase of a chronic myeloid leukaemia&#xD;
&#xD;
          -  Absence of extra-medullary disease (except for a hepatomegaly and/or of a&#xD;
             splenomegaly).&#xD;
&#xD;
          -  Absence of any former treatment of chronic myeloid leukaemia except for hydroxyurea.&#xD;
&#xD;
          -  Stop of hydroxyurea at least week before the beginning of the imatinib mesylate.&#xD;
&#xD;
          -  Diagnosis of chronic myeloid leukaemia in chronic phase recent (less than 2 months).&#xD;
&#xD;
          -  Score of Lansky ≥ 60.&#xD;
&#xD;
          -  Effective contraception among patients in age to procreate.&#xD;
&#xD;
          -  Written voluntary informed consent of the two parents or the legal guardian.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients with grade 3 / 4 cardiac disease.&#xD;
&#xD;
          -  Pathology cardiac, pulmonary, hepatic, renal or neurological of grade &gt; 2 (WHO).&#xD;
&#xD;
          -  Participation in a clinical trial in the 28 days preceding the beginning by the&#xD;
             treatment.&#xD;
&#xD;
          -  Impossible Follow-up during at least 2 years, patient not compliant.&#xD;
&#xD;
          -  Expectant mother or nursing.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>18 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>CHU Amiens</name>
      <address>
        <city>Amiens</city>
        <zip>80000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital La Timone - CHU de Marseille</name>
      <address>
        <city>Marseille</city>
        <zip>13385</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital de Brabois - CHU de Nancy</name>
      <address>
        <city>Vendoeuvre les Nancy</city>
        <zip>54511</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>October 2016</verification_date>
  <study_first_submitted>February 16, 2009</study_first_submitted>
  <study_first_submitted_qc>February 17, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 18, 2009</study_first_posted>
  <last_update_submitted>October 10, 2016</last_update_submitted>
  <last_update_submitted_qc>October 10, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 11, 2016</last_update_posted>
  <responsible_party>
    <name_title>Docteur Frédéric MILLOT/principal investigator</name_title>
    <organization>CHU DE POITIERS</organization>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Leukemia, Myeloid</mesh_term>
    <mesh_term>Leukemia, Myelogenous, Chronic, BCR-ABL Positive</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Imatinib Mesylate</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

